MLLT6 maintains PD-L1 expression and mediates tumor immune resistance

Research output: Contribution to journalResearch articleContributedpeer-review



Tumor cells subvert immune surveillance by harnessing signals from immune checkpoints to acquire immune resistance. The protein PD-L1 is an important component in this process, and inhibition of PD-L1 elicits durable anti-tumor responses in a broad spectrum of cancers. However, immune checkpoint inhibition that target known pathways is not universally effective. A better understanding of the genetic repertoire underlying these processes is necessary to expand our knowledge in tumor immunity and to facilitate identification of alternative targets. Here, we present a CRISPR/Cas9 screen in human cancer cells to identify genes that confer tumors with the ability to evade the cytotoxic effects of the immune system. We show that the transcriptional regulator MLLT6 (AF17) is required for efficient PD-L1 protein expression and cell surface presentation in cancer cells. MLLT6 depletion alleviates suppression of CD8+ cytotoxic T cell-mediated cytolysis. Furthermore, cancer cells lacking MLLT6 exhibit impaired STAT1 signaling and are insensitive to interferon-γ-induced stimulation of IDO1, GBP5, CD74, and MHC class II genes. Collectively, our findings establish MLLT6 as a regulator of oncogenic and interferon-γ-associated immune resistance.


Original languageEnglish
Article numbere50155
JournalEMBO reports
Issue number12
Publication statusPublished - 15 Oct 2020

External IDs

PubMedCentral PMC7726806
Scopus 85092600142


Sustainable Development Goals


  • B7-H1 Antigen/genetics, DNA-Binding Proteins, Humans, Interferon-gamma/genetics, Neoplasm Proteins, Neoplasms/genetics, Signal Transduction